JEANNE DA ROSA OITICICA RAMALHO

(Fonte: Lattes)
Índice h a partir de 2011
11
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/32 - Laboratório de Otorrinolaringologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2011 ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 13 Citação(ões) na Scopus
    Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil
    (2011) MENDES-CORREA, Maria Cassia Jacintho; BITTAR, Roseli Saraiva Moreira; SALMITO, Norma; OITICICA, Jeanne
    Sudden hearing loss is defined as a sensorineural hearing loss, equal to or greater than 30 dB, at three or more consecutive frequencies, which takes place within 72 hours. Both peginterferon and ribavirin are well-known to be associated with significant adverse effects, but sudden hearing loss is uncommon. We report a 65-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon-alpha and ribavirin for chronic hepatitis C. Peginterferon and ribavirin may cause sudden hearing loss that may not recover after discontinuation of therapy. Immediate treatment for all possible etiologies is essential, along with targeted investigations and early referral for an Ear, Nose and Throat specialist. Physicians should be aware of the possible ototoxic effects of peginterferon and ribavirin combination therapy requiring appropriate surveillance.